Phil Wolfson, MD
Phil Wolfson, MD, is president and CEO of the non-profit Ketamine Research Foundation and directs the training of KAP practitioners through The Ketamine Center. Phil’s book, The Ketamine Papers, is the seminal work in the burgeoning ketamine arena. He is principal investigator for the MAPS sponsored Phase 2, the FDA-approved 18-person study of MDMA-Assisted Psychotherapy for individuals with significant anxiety due to life threatening illnesses. His clinical practice with ketamine has informed his leadership role in the development of Ketamine-Assisted Psychotherapy.
Financial: Philip Wolfson is the founder and CEO of The Ketamine Research Foundation. He has an ownership interest in Progressive Therapeutics, Inc. Dr. Wolfson will address off-label uses. He has no relevant financial relationships with ineligible organizations.
Non-financial: Philip Wolfson has no relevant non-financial relationship to disclose.